SEC Filing Summary: Big Rock Partners Acquisition Corp.
Business Context and Reporting Period
This Form 8-K was filed by Big Rock Partners Acquisition Corp. (not NRX Pharmaceuticals, Inc.) on June 20, 2019. The registrant is a Special Purpose Acquisition Company (SPAC) incorporated in Delaware and listed on the NASDAQ. The report details an extension of the deadline to consummate an initial business combination.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial figure disclosed is the extension payment deposited into the trust account:
- Extension Payment: $95,604.56 deposited on June 20, 2019.
- Payment Rate: $0.02 per public share outstanding for each 30-day extension period.
Material Changes
The primary material change is the extension of the termination date for the initial business combination:
- Previous Deadline: August 22, 2019 (as amended on May 21, 2019).
- New Deadline: July 22, 2019.
- Extension Status: This represents the second 30-day extension period. The company retains the option to deposit additional funds for one more 30-day extension.
Outlook and Management Commentary
Management indicates the company must consummate an initial business combination by the new deadline of July 22, 2019, or determine to fund an additional extension. The filing confirms the company is an emerging growth company.
Investor Verification Checklist
- Verify the total number of public shares outstanding to confirm the $95,604.56 payment aligns with the $0.02 per share rate.
- Confirm the current balance in the trust account following the second extension payment.
- Monitor for announcements regarding a potential third extension or a definitive merger agreement before July 22, 2019.
- Review the terms of the Rights (BRPAR) and Warrants (BRPAW) to understand dilution implications if a merger occurs.